JP4473926B1 - Evaluation method of skin darkening tendency by ultraviolet rays - Google Patents

Evaluation method of skin darkening tendency by ultraviolet rays Download PDF

Info

Publication number
JP4473926B1
JP4473926B1 JP2008327376A JP2008327376A JP4473926B1 JP 4473926 B1 JP4473926 B1 JP 4473926B1 JP 2008327376 A JP2008327376 A JP 2008327376A JP 2008327376 A JP2008327376 A JP 2008327376A JP 4473926 B1 JP4473926 B1 JP 4473926B1
Authority
JP
Japan
Prior art keywords
skin
amount
protein
annexin
stratum corneum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008327376A
Other languages
Japanese (ja)
Other versions
JP2010151481A (en
Inventor
知永 安田
耕介 速水
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fancl Corp
Original Assignee
Fancl Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fancl Corp filed Critical Fancl Corp
Priority to JP2008327376A priority Critical patent/JP4473926B1/en
Priority to PCT/JP2009/071125 priority patent/WO2010073984A1/en
Priority to CN200980148442.8A priority patent/CN102239413B/en
Priority to KR1020117012442A priority patent/KR101052171B1/en
Priority to HK11113077.6A priority patent/HK1158753B/en
Application granted granted Critical
Publication of JP4473926B1 publication Critical patent/JP4473926B1/en
Publication of JP2010151481A publication Critical patent/JP2010151481A/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/81Preparation or application process involves irradiation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/20Dermatological disorders
    • G01N2800/207Pigmentation disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Cosmetics (AREA)

Abstract

【課題】紫外線障害リスクを評価する方法を提供する。特に、非侵襲的な手段を用いて採取した皮膚角層を用いて、当該被験者の皮膚黒化傾向を知ることができる手法を提供する。
【解決手段】皮膚角層中のアネキシンII蛋白質量を指標とする皮膚メラニン量を推定する方法、又は、紫外線による皮膚黒化傾向の評価方法。
【選択図】図8
A method for evaluating the risk of UV damage is provided. In particular, the present invention provides a method that can know the skin darkening tendency of the subject using a stratum corneum collected using noninvasive means.
A method for estimating the amount of skin melanin using the amount of annexin II protein in the stratum corneum as an index, or a method for evaluating the tendency of skin darkening due to ultraviolet rays.
[Selection] Figure 8

Description

本発明は、紫外線による皮膚黒化傾向の評価方法に関する。   The present invention relates to a method for evaluating the tendency of skin darkening due to ultraviolet rays.

紫外線には皮膚に対する発ガン作用、白内障等の眼疾患への影響、免疫機能への影響など多くの健康への影響が懸念されている。皮膚においても紫外線にさらされると、様々な紫外線障害を引き起こす。紫外線は皮膚に炎症を起こしたり、皮膚の不飽和脂質を酸化して脂質ラジカルを発生させ、過酸化脂質を生成する。この様な紫外線による炎症や酸化は組織、細胞、DNAの障害を引き起こす。皮膚の紫外線曝露による現象としては一般的に、シワ、シミ、皮膚ガン等が挙げられる。
近年、疫学的なデータとして紫外線に対する感受性の違い(肌の色、スキンタイプ等)により皮膚がんのリスクが高まるとの報告もある(非特許文献1,2)。さらに皮膚ガンの一種である悪性黒色腫(メラノーマ)の危険リスク度はmelanocortin1 receptoerの1塩基置換の遺伝子変異によりリスクが数倍高くなることも明らかとなっている(非特許文献3,4)。紫外線に対する感受性はスキンタイプによって大きく異なり、6段階に分類するタイプ別に分けたり、赤み(紅斑)を生じる最小紫外線エネルギー(最小紅斑量:MED)を目安に行われるが、前者は主観的観測、また後者は紫外線を当てなくては測定できないというリスクが伴う。オゾン層破壊などにより以前にも増して紫外線増加が問題になっており、個人に対する紫外線への感受性リスク評価も適切に行われる必要がある。
一方、一般的にシミと言われている色素沈着ができる初期段階においては皮膚表面に顕在化する前に様々な刺激により表皮角化細胞がα−MSH、bFGF、CGRP、エンドセリンなどの情報伝達物質を生成し、メラノサイトに伝達する。メラノサイトに伝達された後、細胞内においてメラニン色素が大量に作られる。一方、紫外線によってターンオーバーが異常となり大量に作られたメラニン色素が排出できないため色素性病変へと変化する。in vitroの系を用いた実験においてもメラノサイトに紫外線を照射した場合、細胞の増殖因子マーカーである、p73、Nup88、p27、Id1、PCNAが、またアポトーシス関連蛋白質であるbcl−2の発現が増減するという報告がある(非特許文献5)。これまでに、シミの状況をバイオプシーによる皮膚組織を用いて侵襲的にシミ部と正常部を比較し、シミ部においてNT−3、ADAM9、HB−EGFといった蛋白質の発現が顕著に増加しているという報告がある(特許文献1)。さらに、皮膚のシミ形成を予知する検査方法としてバイオプシーによってMLSTD1、MOGAT1、Mcp9、Krt2−6b等のmRNA量を測定し、シミ形成のリスクを判断するという報告がある(特許文献2、3、4)。また、非侵襲的な方法としてテープストリッピングもしくは擦過を介して採取した皮膚に由来する角層を試料として、インターロイキン1(IL−1)とインターロイキン1レセプターアンタゴニスト(IL−1ra)の存在量分析をし、肌質の評価をする方法が特許文献5に開示されている。
There are concerns about many health effects such as carcinogenic effects on the skin, effects on eye diseases such as cataracts, and immune functions. Exposure to UV rays in the skin also causes various UV damages. Ultraviolet rays cause inflammation in the skin, or oxidize unsaturated lipids in the skin to generate lipid radicals, thereby producing lipid peroxides. Such inflammation and oxidation caused by ultraviolet rays cause tissue, cell and DNA damage. Phenomena due to UV exposure of skin generally include wrinkles, spots, skin cancers and the like.
In recent years, as epidemiological data, there is a report that the risk of skin cancer increases due to differences in sensitivity to ultraviolet rays (skin color, skin type, etc.) (Non-Patent Documents 1 and 2). Furthermore, it has also been clarified that the risk level of malignant melanoma (melanoma), which is a type of skin cancer, is several times higher due to the single base substitution gene mutation of melanocortin1 receptor (Non-patent Documents 3 and 4). Sensitivity to ultraviolet rays varies greatly depending on the skin type, and it is classified according to the type classified into 6 stages, and is based on the minimum ultraviolet energy (minimum erythema amount: MED) that causes redness (erythema), but the former is subjective observation, The latter involves the risk that it cannot be measured without exposure to ultraviolet light. The increase in ultraviolet rays has become a problem more than before due to ozone layer destruction, etc., and it is necessary to appropriately evaluate the sensitivity risk to individuals for ultraviolet rays.
On the other hand, in the initial stage where pigmentation is generally said to be a stain, the epidermis keratinocytes may be signaled by α-MSH, bFGF, CGRP, endothelin, etc. by various stimuli before they appear on the skin surface. Is produced and transmitted to melanocytes. After being transmitted to melanocytes, a large amount of melanin is made in the cell. On the other hand, the turnover becomes abnormal due to ultraviolet rays, and the melanin pigment produced in large quantities cannot be discharged, so it changes to a pigmented lesion. In experiments using an in vitro system, when melanocytes were irradiated with ultraviolet rays, the expression of cell growth factor markers, p73, Nup88, p27, Id1, and PCNA, and the expression of bcl-2, an apoptosis-related protein, increased or decreased. (Non-patent document 5). So far, the state of the stain is invasively compared with the normal portion using the skin tissue by biopsy, and the expression of proteins such as NT-3, ADAM9, HB-EGF has been remarkably increased in the stain portion. (Patent Document 1). Furthermore, as a test method for predicting skin spot formation, there is a report of measuring the amount of mRNA such as MLSTD1, MOGAT1, Mcp9, Krt2-6b, etc. by biopsy to judge the risk of spot formation (Patent Documents 2, 3, 4). ). In addition, as a non-invasive method, the abundance analysis of interleukin 1 (IL-1) and interleukin 1 receptor antagonist (IL-1ra) is performed using a stratum corneum derived from the skin collected through tape stripping or abrasion as a sample. A method for evaluating skin quality is disclosed in Patent Document 5.

特開2004−205246号公報JP 2004-205246 A 特開2005−106745号公報JP 2005-106745 A 特開2005−110505号公報JP 2005-110505 A 特開2007−289063号公報JP 2007-289063 A 特許第3590708号公報Japanese Patent No. 3590708 Arch Dermatol.2004;140:819−824Arch Dermatol. 2004; 140: 819-824. Cancer Causes Control.1997;8 (2):246−252Cancer Causes Control. 1997; 8 (2): 246-252 Invest Dermatol. 117:294−300,2001Invest Dermatol. 117: 294-300, 2001 Am.J.Hum.Genet.66:176−186,2000Am. J. et al. Hum. Genet. 66: 176-186,2000 Carcinogenesis 24(12):1929−1934,2003Carcinogenesis 24 (12): 1929-934, 2003

本発明は、紫外線障害リスクを評価する方法を提供する。特に、非侵襲的な手段を用いて採取した皮膚角層を用いて、当該被験者の皮膚黒化傾向を知るための手法を提供することを目的とする。   The present invention provides a method for assessing the risk of UV damage. In particular, an object is to provide a method for knowing the skin darkening tendency of the subject using a stratum corneum collected using non-invasive means.

本発明の主な構成は、次のとおりである。
(1)皮膚角層中のアネキシンII蛋白質量と、紫外線照射後、日数が経過したときのメラニン量とが正の相関を示すことを利用し、皮膚角層中のアネキシンII蛋白質量を測定して皮膚の紫外線による皮膚黒化傾向を評価することを特徴とする紫外線による皮膚黒化傾向の評価方法。
(2)皮膚角層中のアネキシンII蛋白質量と、紫外線照射後、日数が経過したときのメラニン量とが正の相関を示すことを利用し皮膚角層中のアネキシンII蛋白質量に影響を与える成分を判別して皮膚黒化を抑制する成分をスクリーニングする方法。
(3)()に記載された皮膚黒化傾向の評価方法を用いて得られた皮膚黒化傾向に応じて化粧料を選択する方法。
The main configuration of the present invention is as follows.
(1) Using the fact that the amount of Annexin II protein in the skin stratum corneum is positively correlated with the amount of melanin when the number of days has elapsed after UV irradiation, the amount of Annexin II protein in the skin stratum corneum is measured. A method for evaluating the tendency of skin darkening due to ultraviolet rays, wherein the tendency of skin darkening due to ultraviolet rays is evaluated.
(2) Using the fact that the amount of Annexin II protein in the stratum corneum is positively correlated with the amount of melanin when the number of days has elapsed after UV irradiation, the amount of Annexin II protein in the skin stratum corneum is affected. A method of screening for ingredients that suppress skin darkening by discriminating the ingredients to be applied.
(3) A method of selecting a cosmetic according to the skin darkening tendency obtained by using the method for evaluating skin darkening described in ( 1 ).

本発明は、生体内において発現している蛋白質であるアネキシンII蛋白質量が紫外線被曝によるメラニン量の生成と正の相関関係があることを知見し、皮膚黒化傾向を評価できることを明らかにしたものである。
本発明により、紫外線を実際に照射することなく、紫外線による皮膚黒化傾向を評価することができる。
本発明は、非侵襲的なテープストリッピング手段を用いて採取した皮膚角層を用いて評価することができるので、安全かつ簡便である。
また、本発明の評価法を利用して、紫外線による皮膚黒化傾向の抑制あるいは紫外線被曝後のメラニン生成抑制に有用な成分をスクリーニングすることができる。
本発明により、シミ対策、シミ予防の美容が容易となる。即ち、シミ等色素沈着部位に対する化粧料、医薬部外品、医薬品又は美容用健康食品の選択及びそのために有効な情報を提供することができる。シミ対策等の美容カウンセリングを的確に行うことができる。
The present invention has found that the amount of Annexin II protein, which is a protein expressed in vivo, has a positive correlation with the production of melanin by UV exposure, and has clarified that the tendency of skin darkening can be evaluated It is.
According to the present invention, the tendency of skin darkening due to ultraviolet rays can be evaluated without actually irradiating the ultraviolet rays.
Since the present invention can be evaluated using the stratum corneum collected using a noninvasive tape stripping means, it is safe and simple.
In addition, by using the evaluation method of the present invention, it is possible to screen for a component useful for suppressing the tendency of skin darkening due to ultraviolet rays or suppressing melanin production after exposure to ultraviolet rays.
According to the present invention, it is easy to make a beauty for preventing spots and preventing spots. That is, it is possible to provide selection of cosmetics, quasi-drugs, pharmaceuticals or beauty health foods for pigmentation sites such as spots and information effective for that purpose. Beauty counseling such as anti-smudge can be performed accurately.

以下、本発明の実施の形態についてより詳細に説明する。
本発明は、皮膚角層中に含まれるアネキシンII蛋白質量を測定することを含む、紫外線障害リスクを評価する方法を提供する。
本願発明は、非侵襲的な手法により採取した皮膚角層中に存在するタンパク質であるアネキシンIIを計測した存在量に基づいて、紫外線曝露によって当該皮膚角層の出所元となった人が黒化するリスクを知ることができるものである。
本発明者は、曝露後のメラニン生成の変化とアネキシンIIの発現量が正の相関があることを知見し、アネキシンIIの発現量を測定することにより、曝露した場合にメラニンが生成するリスク、更に皮膚が黒化する程度を予測できることを明らかにした。
この結果に基づき、皮膚角層中のアネキシンIIの発現量を知ることにより、紫外線曝露の影響を抑制する化粧料の選択などの予防措置を講ずることができる。また、紫外線曝露による影響の予想にあわせて、対策を検討することが可能となる。即ち、本発明により、シミ対策、シミ予防の美容が容易となる。さらには、シミ等色素沈着部位に対する化粧料、医薬部外品、医薬品又は美容用健康食品の選択及びそのために有効な情報を提供することができる。シミ対策等の美容カウンセリングを科学的な根拠をもって的確に行うことができる。
またアネキシンII高発現産生培養皮膚モデルを利用して、このアネキシンIIタンパク質の発現量に影響を与える被検査物質を探索することにより、メラニンの生成を抑制できる薬剤をスクリーニングすることができる。
本願発明は、テープストリッピング等の被侵襲的な方法によって安全に容易に皮膚角層を採取して、その皮膚角層を短時間に、注目するアネキシンIIタンパク質の発現量を特定することができるので、化粧品売り場等で簡単に測定して、その場で化粧料選択資料に利用することができる。このアネキシンIIタンパク質の発現量を測定する機器は、検出した結果と指標とを比較して提示することができる。更に、この結果に基づいて、適した化粧料やメニューを表示することもできる。
Hereinafter, embodiments of the present invention will be described in more detail.
The present invention provides a method for evaluating the risk of UV damage, which comprises measuring the amount of annexin II protein contained in the stratum corneum.
The invention of the present application is based on the abundance obtained by measuring annexin II, a protein present in the skin stratum corneum collected by a non-invasive technique, and the person who originated the skin stratum corneum by exposure to ultraviolet rays is blackened. It is possible to know the risk of doing.
The present inventor has found that there is a positive correlation between the change in melanin production after exposure and the expression level of annexin II, and by measuring the expression level of annexin II, the risk of melanin formation when exposed, Furthermore, it was clarified that the degree of skin darkening can be predicted.
Based on this result, knowing the expression level of annexin II in the stratum corneum, it is possible to take preventive measures such as selection of cosmetics that suppress the effects of UV exposure. In addition, measures can be considered in accordance with the expected impact of UV exposure. That is, according to the present invention, it is possible to easily make a beauty for preventing spots and preventing spots. Furthermore, it is possible to provide selection of cosmetics, quasi-drugs, pharmaceuticals or beauty health foods for pigmentation sites such as spots and information effective for that purpose. Beauty counseling, such as anti-smudge measures, can be performed accurately on a scientific basis.
Further, by using an annexin II high-expression production cultured skin model and searching for a test substance that affects the expression level of the annexin II protein, a drug capable of suppressing the production of melanin can be screened.
In the present invention, it is possible to safely and easily collect the skin stratum corneum by a invasive method such as tape stripping, and to specify the expression level of the annexin II protein of interest in the skin stratum corneum in a short time. It can be easily measured at a cosmetics department, etc., and used as a cosmetic selection material on the spot. The instrument that measures the expression level of the annexin II protein can present the detected result in comparison with the index. Furthermore, suitable cosmetics and menus can be displayed based on this result.

アネキシンIIは、分子質量38,473Daの細胞内蛋白質で、カルシウムで制御される膜結合蛋白質であり、この蛋白質に二つのカルシウムイオンが結合する。2組あるアネキシンリピートのうち、一つはカルシウムが結合し、一つはリン脂質が結合する。この蛋白質は細胞膜にあるリン脂質に結合しているアクチンや細胞骨格系の蛋白質と架橋したり、t−PA (tissue plasminogen activator)を介してプラスミノーゲンを活性化したりする。遺伝子塩基配列情報(Annexin A2 ,Gene 95:243−251(1990), BC015834)。アミノ酸配列情報(Annexin A2, J.Biol. Chem.266:5169−5176(1991), P07355)。   Annexin II is an intracellular protein having a molecular mass of 38,473 Da and is a membrane-bound protein controlled by calcium, and two calcium ions bind to this protein. Of the two sets of annexin repeats, one binds calcium and one binds phospholipids. This protein crosslinks with actin and cytoskeletal proteins bound to phospholipids in the cell membrane, or activates plasminogen via t-PA (tissue plasminogen activator). Gene base sequence information (Annexin A2, Gene 95: 243-251 (1990), BC015834). Amino acid sequence information (Annexin A2, J. Biol. Chem. 266: 5169-5176 (1991), P07355).

皮膚角層から角層蛋白質を採取する方法
(1)テープストリッピング法による角層の採取
テープストリッピング法とは皮膚に粘着テープを貼り付けて、粘着テープを剥がすことにより、粘着面に粘着した角層を採取する方法である。
市販の粘着テープを用いて、例えばヒト頬部に粘着テープを押し付けることにより、角層を粘着テープに粘着させて採取することができる。市販の粘着テープとしてはアサヒバイオメッド社製角質チェッカー、モリテックス社製角層シール、PROMOTOOL社製角質チェッカー(ディスクタイプW、ディスクタイプG、PROタイプ)、Integral社製Corneofix、3M社製透明テープ、3M社製透明両面テープ等が挙げられる。
Method of collecting stratum corneum protein from skin stratum corneum (1) Extraction of stratum corneum by tape stripping method The tape stripping method is a stratum corneum that adheres to the adhesive surface by applying an adhesive tape to the skin and peeling off the adhesive tape. It is a method to collect.
By using a commercially available adhesive tape, for example, by pressing the adhesive tape against the human cheek, the stratum corneum can be adhered to the adhesive tape and collected. As commercially available adhesive tapes, Asahi Biomed's horny checker, Moritex's horny layer seal, PROMOTOOL's horny checker (disk type W, disk type G, PRO type), Integral Corneofix, 3M transparent tape, Examples thereof include a transparent double-sided tape manufactured by 3M.

(2)抽出バッファー
粘着テープに粘着した角層から角層蛋白質を抽出するために抽出バッファーを用いる。抽出バッファーとして例えば以下の組成を挙げることができる。組成:PBS(−)、0.1%SDS。
粘着テープで採取されてくる皮膚の角質層は角化細胞が分化したもので、細胞骨格系の蛋白質を多く含む。そのため角層蛋白質の抽出効率を上げるには、この抽出バッファーに適当な界面活性剤を含有させることが好ましい。界面活性剤としてはSDS(ラウリル硫酸ナトリウム、CH3(CH2)11OSO3Na)を使用することが好ましい。
(2) Extraction buffer An extraction buffer is used to extract stratum corneum protein from the stratum corneum adhered to the adhesive tape. Examples of the extraction buffer include the following compositions. Composition: PBS (-), 0.1% SDS.
The stratum corneum of skin collected with adhesive tape is a differentiated keratinocyte and contains a lot of cytoskeletal proteins. Therefore, in order to increase the extraction efficiency of the stratum corneum protein, it is preferable to contain an appropriate surfactant in this extraction buffer. As the surfactant, SDS (sodium lauryl sulfate, CH 3 (CH 2 ) 11 OSO 3 Na) is preferably used.

(3)角層蛋白質の抽出
角層を採取した粘着テープを円筒容器に入れて、高速回転するホモジナイゼーション用のペッスル(以下、「ペッスル」と呼ぶ)を用いて粘着面を擦ることにより迅速に角層蛋白質の抽出が可能である。粘着テープは粘着面を円筒容器内側に向けて、粘着面の反対面を円筒容器の内側に沿わせるようにして、円筒容器に入れる。粘着テープを粘着面の反対面を円筒容器の内側に沿わせて入れることにより、ペッスルにより容易に粘着面を擦ることができる。この他の方法として、角層を採取した粘着テープを抽出バッファーに浸してスクレーパーで擦って角層蛋白質を抽出しても良く、振盪法や超音波法を用いても良い。
(3) Extraction of stratum corneum protein Place the adhesive tape from which the stratum corneum has been collected into a cylindrical container and quickly rub the adhesive surface with a high-speed rotating homogenization pestle (hereinafter referred to as “Pessle”). In addition, stratum corneum protein can be extracted. The adhesive tape is placed in the cylindrical container, with the adhesive surface facing the inside of the cylindrical container and the opposite surface of the adhesive surface along the inside of the cylindrical container. By placing the adhesive tape with the opposite surface of the adhesive surface along the inside of the cylindrical container, the adhesive surface can be easily rubbed with the pestle. As another method, the stratum corneum protein may be extracted by immersing an adhesive tape from which the stratum corneum has been collected in an extraction buffer and rubbing with a scraper, or using a shaking method or an ultrasonic method.

(4)角層蛋白質抽出液の回収
角層蛋白質抽出液を約1分間静置し、泡を沈静化し、その後、円筒容器から角層蛋白質抽出液を吸引して回収することが好ましい。
(4) Recovery of stratum corneum protein extract It is preferable that the stratum corneum protein extract is allowed to stand for about 1 minute to calm the foam, and then the stratum corneum protein extract is sucked and recovered from the cylindrical container.

(5)角層蛋白質中のアネキシンII蛋白質量の分析
得られた角層蛋白質抽出液中のアネキシンII蛋白質量は、免疫ブロッティング法、ELISA法、抗体チップ法、FRET法により定量分析することができる。
(5) Analysis of Annexin II protein content in stratum corneum protein The amount of Annexin II protein in the obtained stratum corneum protein extract can be quantitatively analyzed by immunoblotting method, ELISA method, antibody chip method, FRET method. .

紫外線による皮膚黒化傾向の評価
本発明により、皮膚角層中のアネキシンII蛋白質量と、1MED(最小紅斑量)の紫外線照射後の皮膚明度が負の相関関係を有することが明らかとなった。また、皮膚角層中のアネキシンII蛋白質量と、1MED(最小紅斑量)の紫外線照射後のメラニン量(メグザメーターで測定したN値)が正の相関を有することが明らかとなった。
従って、皮膚角層中のアネキシンII蛋白質量が平均値よりも高い場合には、皮膚の紫外線による皮膚黒化傾向が強いと評価できる。具体的には、皮膚角層中のアネキシンII蛋白質量が平均値よりも高い人は、紫外線曝露によってメラニン産生が亢進され易く、シミ等の紫外線障害が生じ易いと評価できる。
Evaluation of skin darkening tendency by ultraviolet rays According to the present invention, it has been clarified that the amount of annexin II protein in the stratum corneum and the skin brightness after ultraviolet irradiation of 1 MED (minimum erythema amount) have a negative correlation. It was also revealed that the amount of Annexin II protein in the stratum corneum and the amount of melanin (N value measured with a meggerometer) after irradiation with 1 MED (minimum erythema amount) had a positive correlation.
Therefore, when the amount of annexin II protein in the stratum corneum is higher than the average value, it can be evaluated that the skin darkening tendency by ultraviolet rays of the skin is strong. Specifically, it can be evaluated that a person whose annexin II protein amount in the horny layer of the skin is higher than the average value is likely to increase melanin production by UV exposure and to easily cause UV damage such as spots.

紫外線による皮膚黒化の抑制剤のスクリーニング
マウス等の皮膚角層中のアネキシンII蛋白質量を減少させる成分を探索することにより、紫外線による皮膚黒化の抑制剤をスクリーニングすることができる。
Screening for inhibitors of skin darkening caused by ultraviolet rays By searching for components that reduce the amount of annexin II protein in the stratum corneum of mice and the like, inhibitors for skin darkening caused by ultraviolet rays can be screened.

1.被験者
20代と30代の男性10名を被験者とした。各被験者の年齢、スキンタイプ、最小紅斑量、紫外線照射前のL*値、N値を表1に示す。また、スキンタイプのIIは「簡単にサンバーン(Sunburn)を起こし、僅かにサンタン(Suntan)を起こす」タイプ、IIIは「普通にサンバーンを起こし、普通にサンタンを起こす(薄茶色の日焼け)」タイプ、IVは「僅かにサンバーンを起こし、常にサンタンを起こす(茶色の日焼け)」タイプである。
なお、L*値は分光測色計(CM−500、コニカミノルタ社製)で測定したL*a*b*表色系の明度であり、L*値が大きいと明るく(黒化していない)、L*値が小さいと暗い(黒化している)と評価できる。また、N値はメラニン量の指標であり、Courage+Khazaka製mexameterMX16を用いて測定した。N値が大きいほど、黒化しており、N値が小さいとメラニン量が少なく色白であると評価できる。
1. Subjects Ten men in their 20s and 30s were subjects. Table 1 shows the age, skin type, minimum erythema amount, L * value and N value before ultraviolet irradiation of each subject. In addition, skin type II is a type that easily causes sunburn and slightly causes suntan, and III is a type that normally causes sunburn and usually causes suntan (light brown tanning). , IV is a type of “slightly sunburn and always suntan (brown tan)”.
The L * value is the brightness of the L * a * b * color system measured with a spectrocolorimeter (CM-500, manufactured by Konica Minolta Co., Ltd.). When the L * value is large, it is bright (not blackened). When the L * value is small, it can be evaluated as dark (blackened). The N value is an index of the amount of melanin, and was measured using a Mexmeter MX16 manufactured by Course + Khazaka. The larger the N value is, the more black it is. When the N value is small, the amount of melanin is small and it can be evaluated that it is fair.

2.皮膚角層中のアネキシンII蛋白質量の測定
2.1 テープストリッピングによる角層の採取
粘着テープとしてアサヒバイオメッド社製角質チェッカー(2.5cm×2.5cm)を用いた。被験者の背部に角質チェッカーを貼り、指先で軽く擦り付けて皮膚角層を角質チェッカーの粘着面に粘着させ、合計5枚のテープストリッピングを背部から採取した。 また、テープストリッピングからの採取箇所は紫外線照射部位から採取した。
2. Measurement of annexin II protein amount in the horny layer of skin 2.1 Collection of horny layer by tape stripping A horny checker (2.5 cm × 2.5 cm) manufactured by Asahi Biomed Co., Ltd. was used as an adhesive tape. A keratin checker was affixed to the back of the subject, lightly rubbed with a fingertip to adhere the skin stratum corneum to the adhesive surface of the horny checker, and a total of five tape strips were collected from the back. In addition, the sampling location from tape stripping was sampled from the ultraviolet irradiation site.

2.2 皮膚角層蛋白質の抽出
抽出バッファー:PBS(−)、 0.1%(w/v)SDS。
抽出バッファー量:200μL。
抽出容器:直径11mmの円筒容器。
円筒容器に粘着テープを粘着面の反対の面が容器の内壁に沿うようにして入れ、抽出バッファーを入れて、ミニ・コードレスグラインダー(フナコシ社 code13753E)にペッスルとしてHandy pestle (TOYOBO社、code HMX−301)を接続し、ペッスルを9000rpmで回転させて、円筒容器内壁に沿わせた粘着テープの粘着面を擦った。攪拌時間は90秒とした。
皮膚角層蛋白質抽出液を約1分間静置し、泡を沈静化し、その後、円筒容器から皮膚角層蛋白質抽出液を吸引して回収した。
2.2 Extraction of skin stratum corneum protein Extraction buffer: PBS (−), 0.1% (w / v) SDS.
Extraction buffer volume: 200 μL.
Extraction container: cylindrical container with a diameter of 11 mm.
Adhesive tape is put in a cylindrical container so that the surface opposite to the adhesive surface is along the inner wall of the container, an extraction buffer is placed, and a handy pestle (TOYOBO, code HMX-) is used as a pestle in a mini cordless grinder (Funakoshi code13753E). 301) was connected, the pestle was rotated at 9000 rpm, and the adhesive surface of the adhesive tape along the inner wall of the cylindrical container was rubbed. The stirring time was 90 seconds.
The skin stratum corneum protein extract was allowed to stand for about 1 minute to calm the foam, and then the skin stratum corneum protein extract was aspirated and collected from the cylindrical container.

3.皮膚角層蛋白質量の測定
皮膚角層蛋白質抽出液に含まれる全蛋白質量をDC protein Assay Kit(BIO−RAD社)を用いて測定した。
3. Measurement of skin stratum corneum protein mass The total protein mass contained in the skin stratum corneum protein extract was measured using DC protein Assay Kit (BIO-RAD).

4.皮膚角層蛋白質中のアネキシンII蛋白質量測定
皮膚角層蛋白質量1μg分を用いて免疫ブロッティングによるアネキシンIIの発現量を測定した。各被験者の皮膚角層蛋白質1μg分を用いて5−15%グラジエントゲルを用いてSDS−PAGEによって分離後、蛋白質をPVDF膜に転写し、5%スキムミルクでブロッキングを行った。1次抗体(アネキシンIIポリクローナル抗体:Santa Cruz Biotechnology社製)を1000倍希釈、2次抗体(HRP-ラビットanti−Goat IgG:ZYMED Laboratories社製)を10000倍希釈で反応させた後、ECLplus(BD Bioscience社製)にて検出を行った。得られたバンドの強度は画像解析ソフトNIH−Image(NIH製)にて数値化を行った。この数値をアネキシンII蛋白質量とした。
4). Annexin II protein mass measurement in skin stratum corneum protein The expression level of Annexin II by immunoblotting was measured using 1 μg of skin stratum corneum protein mass. After separation by SDS-PAGE using 5-15% gradient gel using 1 μg of skin horny layer protein of each subject, the protein was transferred to a PVDF membrane and blocked with 5% skim milk. The primary antibody (Annexin II polyclonal antibody: manufactured by Santa Cruz Biotechnology) was diluted 1000 times, and the secondary antibody (HRP-rabbit anti-Goat IgG: manufactured by ZYMED Laboratories) was reacted at a dilution of 10,000 times, and then ECLplus (BD Detection was performed by Bioscience). The intensity of the obtained band was quantified with image analysis software NIH-Image (manufactured by NIH). This value was defined as annexin II protein mass.

5.紫外線照射
被験者の背部の直径約8mmの円内に1MEDの紫外線を照射した。紫外線照射装置はsolar light company製 Multiple Solar Ultraviolet Simulator Model 601を用いた。紫外線強度はsolar light company製 Erythema UV & UVAIntensity Meter Model 3D−600 v2.0を用いて設定した。
5). Ultraviolet irradiation A 1 MED ultraviolet ray was irradiated in a circle having a diameter of about 8 mm on the back of the subject. As the ultraviolet irradiation device, a Multiple Solar Ultraviolet Simulator Model 601 manufactured by solar light company was used. The ultraviolet intensity was set using Erythema UV & UVA Intensity Meter Model 3D-600 v2.0 manufactured by solar light company.

6.皮膚明度の測定
分光側色計(CM−500、コニカミノルタ社製)を用いて紫外線照射部位および非照射部位のL*値を測定した。紫外線照射前、照射後2、4、7、10、14日目の紫外線照射部位および非照射部位のL*値を測定し、同日内で照射部位と非照射部位のL*の差を測定日のL*変化量として解析に用いた。
6). Measurement of skin lightness Using a spectroscopic colorimeter (CM-500, manufactured by Konica Minolta), L * values of the ultraviolet irradiation site and the non-irradiation site were measured. Measure the L * values of the irradiated and non-irradiated sites on the second, fourth, seventh, tenth, and fourteenth days before and after the irradiation, and measure the difference in L * between the irradiated and non-irradiated sites within the same day The amount of change in L * was used for analysis.

7.皮膚メラニン量の測定
Courage+Khazaka製mexameterMX16を用いて、メラニン量の指標となるN値を測定した。N値は波長568〜660nmの光の反射率である。
紫外線照射前、照射後2、4、7、10、14日目の紫外線照射部位および非照射部位のN値を測定し、同日内で照射部位と非照射部位のN値の差を測定日のN値変化量として解析に用いた。
7). Measurement of skin melanin amount N value serving as an index of the amount of melanin was measured by using Mexmeter MX16 manufactured by Curage + Khazaka. The N value is the reflectance of light having a wavelength of 568 to 660 nm.
Measure the N value of the irradiated and non-irradiated sites on the second, fourth, seventh, tenth, and fourteenth days before and after the irradiation, and determine the difference in N values between the irradiated and non-irradiated sites on the same day. It was used for analysis as an N value change amount.

8.皮膚明度の測定結果
紫外線照射後のL*値の変化量を図1に示す。
L*値の変化量(紫外線照射後のL*値−紫外線照射前のL*値)は紫外線照射2日目に負の値が最大になり、その後、14日目にほぼ回復した。紫外線照射2日目のL*値が最も低く、皮膚が黒化していることを反映している。
0日目のL*値とアネキシンIIの角層中の発現量の相関関係、並びに、2日目、4日目、7日目、10日目、14日目のL*値の変化量と自然対数変換したアネキシンII蛋白質量の相関関係を調べた。回帰直線のグラフを図2〜7に、相関係数を表2に示す。
自然対数変換したアネキシンII蛋白質量と2、10、14日目のL*値の変化量は「かなりの負の相関」を示し、4、7日目のL*値の変化量は「強い負の相関」を示した。
以上のことから、皮膚角層中のアネキシンII蛋白質量が多いほど、紫外線曝露によるL*値の低下(皮膚黒化)傾向が強いことが分かる。皮膚角層中のアネキシンII蛋白質量は紫外線曝露による皮膚黒化傾向の指標となることが判明した。
8). Measurement result of skin brightness FIG. 1 shows the amount of change in L * value after UV irradiation.
The amount of change in the L * value (L * value after UV irradiation-L * value before UV irradiation) became a maximum negative value on the second day of UV irradiation, and then almost recovered on the 14th day. The L * value on the second day of UV irradiation is the lowest, reflecting the darkening of the skin.
Correlation between the L * value on day 0 and the expression level of annexin II in the stratum corneum, and the amount of change in L * value on day 2, day 4, day 7, day 10, and day 14 The correlation of the natural logarithmized annexin II protein mass was investigated. The regression line graphs are shown in FIGS.
The natural logarithmized annexin II protein mass and the amount of change in L * values on days 2, 10 and 14 show a “significant negative correlation”, and the amount of change in L * values on days 4 and 7 is “strong negative” Correlation ”.
From the above, it can be seen that the greater the amount of Annexin II protein in the stratum corneum, the stronger the tendency of L * value reduction (skin darkening) due to UV exposure. It was found that the amount of annexin II protein in the stratum corneum is an index of the tendency of skin darkening due to exposure to ultraviolet rays.

一般的に、相関係数は以下のように評価されている。
0〜0.2 : ほとんど相関無し、
0.2〜0.4 : やや相関あり、
0.4〜0.7 : かなりの正の相関あり、
0.7〜1 : 強い正の相関
0〜-0.2 : ほとんど相関無し、
-0.4〜-0.2 : やや相関あり、
-0.7〜−0.4: かなりの負の相関あり、
−1〜−0.7: 強い負の相関
In general, the correlation coefficient is evaluated as follows.
0 to 0.2: almost no correlation,
0.2-0.4: Somewhat correlated,
0.4-0.7: There is a considerable positive correlation,
0.7-1: Strong positive correlation
0--0.2: Almost no correlation,
-0.4 to -0.2: Somewhat correlated,
-0.7 to -0.4: There is a considerable negative correlation,
−1 to −0.7: Strong negative correlation

9.皮膚メラニン量の測定結果
紫外線照射後のN値の変化量を図8に示す。
N値の変化量(紫外線照射後のN値−紫外線照射前のN値)は紫外線照射4日目以降14日目まで、紫外線照射前(0日目)と比べて高い値を示した。紫外線照射4日目以降14日目まで皮膚メラニン量が多く、皮膚の黒化を反映している。
0日目のN値とアネキシンIIの角層中の発現量の相関関係、並びに、0日目のN値を基準とした、2日目、4日目、7日目、10日目、14日目のN値の変化量と自然対数変換したアネキシンII蛋白質量の相関関係を調べた。回帰直線のグラフを図9〜14に、相関係数を表3に示す。
4日目以降、自然対数変換したアネキシンII蛋白質量とN値の変化量は強い正の相関を示した。
従って、アネキシンII蛋白質量の増加は紫外線曝露によるメラニン量の増加を意味する。すなわち、アネキシンIIが増加すると紫外線曝露によるメラニンの増加並びに皮膚の黒化が増大することが判明した。つまり、アネキシンII蛋白質量は紫外線曝露による皮膚の黒化傾向を反映し、さらにはメラニンの増加の指標となりうることが明らかである。
9. Measurement result of skin melanin amount The amount of change in N value after ultraviolet irradiation is shown in FIG.
The amount of change in N value (N value after ultraviolet irradiation-N value before ultraviolet irradiation) was higher than that before ultraviolet irradiation (day 0) from the 4th day to the 14th day of ultraviolet irradiation. The amount of skin melanin is large from the 4th day to the 14th day from the ultraviolet irradiation, which reflects the darkening of the skin.
Correlation between the N value on day 0 and the expression level of annexin II in the stratum corneum, and the 2nd day, 4th day, 7th day, 10th day, 14 days based on the N value on day 0 The correlation between the amount of change in N value on the day and the amount of Annexin II protein converted to natural logarithm was examined. The regression line graphs are shown in FIGS.
From the fourth day onward, the natural logarithmized annexin II protein mass and the amount of change in N value showed a strong positive correlation.
Therefore, an increase in the annexin II protein amount means an increase in the amount of melanin by exposure to ultraviolet rays. That is, when Annexin II increased, it became clear that the increase in melanin by exposure to ultraviolet rays and the darkening of skin increased. In other words, it is clear that the amount of annexin II protein reflects the tendency of skin darkening due to UV exposure and can be an index of melanin increase.

以上、アネキシンII蛋白質量とL*値の変化、並びにアネキシンII蛋白質量とN値の変化の関係から、皮膚角層中のアネキシンII蛋白質量は、紫外線曝露による皮膚の黒化度の指標となることが判明した。 As described above, from the relationship between Annexin II protein mass and L * value change, and Annexin II protein mass and N value change, Annexin II protein mass in the skin stratum corneum is an indicator of the degree of skin darkening due to UV exposure. It has been found.

紫外線照射後のL*値の変化量示すグラフ。縦軸はL*値の変化量示す。The graph which shows the variation | change_quantity of L * value after ultraviolet irradiation. The vertical axis indicates the amount of change in the L * value. 紫外線照射直前(0日目)のL*値とアネキシンIIの角層中の発現量の相関関係を示すグラフGraph showing the correlation between the L * value immediately before UV irradiation (day 0) and the expression level of Annexin II in the stratum corneum 0日目のN値を基準とした紫外線照射後2日目のL*値の変化量と自然対数変換したアネキシンII蛋白質量の相関関係を示すグラフGraph showing the correlation between the amount of change in L * value on the second day after ultraviolet irradiation and the natural logarithmically converted Annexin II protein amount based on the N value on Day 0 0日目のN値を基準とした紫外線照射後4日目のL*値の変化量と自然対数変換したアネキシンII蛋白質量の相関関係を示すグラフGraph showing the correlation between the amount of change in L * value on the 4th day after ultraviolet irradiation and the natural logarithmized annexin II protein amount based on the N value on the 0th day 0日目のN値を基準とした紫外線照射後7日目のL*値の変化量と自然対数変換したアネキシンII蛋白質量の相関関係を示すグラフGraph showing the correlation between the amount of change in L * value on the 7th day after ultraviolet irradiation and the natural logarithmically converted Annexin II protein amount based on the N value on the 0th day 0日目のN値を基準とした紫外線照射後10日目のL*値の変化量と自然対数変換したアネキシンII蛋白質量の相関関係を示すグラフGraph showing the correlation between the amount of change in L * value on the 10th day after UV irradiation and the amount of natural log-transformed Annexin II protein based on the N value on the 0th day 0日目のN値を基準とした紫外線照射後14日目のL*値の変化量と自然対数変換したアネキシンII蛋白質量の相関関係を示すグラフGraph showing the correlation between the amount of change in L * value on the 14th day after ultraviolet irradiation and the natural logarithmized annexin II protein amount based on the N value on the 0th day 紫外線照射後のN値の経時変化量を示すグラフ。縦軸はN値の変化量を示す。The graph which shows the amount of time-dependent change of N value after ultraviolet irradiation. The vertical axis indicates the amount of change in N value. 紫外線照射直前(0日目)のN値とアネキシンIIの角層中の発現量の相関関係を示すグラフGraph showing the correlation between the N value immediately before UV irradiation (day 0) and the expression level of Annexin II in the stratum corneum 0日目のN値を基準とした紫外線照射後2日目のN値の変化量と自然対数変換したアネキシンII蛋白質量の相関関係を示すグラフGraph showing the correlation between the amount of change in N value on the second day after ultraviolet irradiation and the amount of natural log-transformed annexin II protein based on the N value on day 0 0日目のN値を基準とした紫外線照射後4日目のN値の変化量と自然対数変換したアネキシンII蛋白質量の相関関係を示すグラフGraph showing the correlation between the amount of change in N value on the 4th day after UV irradiation and the natural log-transformed Annexin II protein amount based on the N value on Day 0 0日目のN値を基準とした紫外線照射後7日目のN値の変化量と自然対数変換したアネキシンII蛋白質量の相関関係を示すグラフGraph showing the correlation between the amount of change in N value on the 7th day after UV irradiation and the natural logarithmically converted Annexin II protein amount based on the N value on Day 0 0日目のN値を基準とした紫外線照射後10日目のN値の変化量と自然対数変換したアネキシンII蛋白質量の相関関係を示すグラフGraph showing the correlation between the amount of change in N value on the 10th day after UV irradiation and the natural logarithmically converted Annexin II protein amount based on the N value on Day 0 0日目のN値を基準とした紫外線照射後14日目のN値の変化量と自然対数変換したアネキシンII蛋白質量の相関関係を示すグラフGraph showing the correlation between the amount of change in N value on day 14 after UV irradiation and the amount of annexin II protein converted to natural logarithm on the basis of N value on day 0

Claims (3)

皮膚角層中のアネキシンII蛋白質量と、紫外線照射後、日数が経過したときのメラニン量とが正の相関を示すことを利用し、皮膚角層中のアネキシンII蛋白質量を測定して皮膚の紫外線による皮膚黒化傾向を評価することを特徴とする紫外線による皮膚黒化傾向の評価方法。 Using the fact that the amount of Annexin II protein in the stratum corneum is positively correlated with the amount of melanin when the number of days has elapsed after UV irradiation, the amount of Annexin II protein in the skin stratum corneum is measured and A method for evaluating the tendency of skin darkening due to ultraviolet rays, characterized by evaluating the tendency of skin darkening due to ultraviolet rays. 皮膚角層中のアネキシンII蛋白質量と、紫外線照射後、日数が経過したときのメラニン量とが正の相関を示すことを利用し皮膚角層中のアネキシンII蛋白質量に影響を与える成分を判別して皮膚黒化を抑制する成分をスクリーニングする方法。 Using the fact that the amount of annexin II protein in the skin stratum corneum is positively correlated with the amount of melanin when the number of days has elapsed after UV irradiation , an ingredient that affects the amount of annexin II protein in the skin stratum corneum A method of screening for ingredients that are discriminated and suppress skin darkening . 請求項に記載された皮膚黒化傾向の評価方法を用いて得られた皮膚黒化傾向に応じて化粧料を選択する方法。 The method to select cosmetics according to the skin darkening tendency obtained using the evaluation method of the skin darkening tendency described in Claim 1 .
JP2008327376A 2008-12-24 2008-12-24 Evaluation method of skin darkening tendency by ultraviolet rays Expired - Fee Related JP4473926B1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2008327376A JP4473926B1 (en) 2008-12-24 2008-12-24 Evaluation method of skin darkening tendency by ultraviolet rays
PCT/JP2009/071125 WO2010073984A1 (en) 2008-12-24 2009-12-18 Method for evaluating tendency to skin pigmentation by ultraviolet light
CN200980148442.8A CN102239413B (en) 2008-12-24 2009-12-18 Method for evaluating skin darkening tendency due to ultraviolet rays
KR1020117012442A KR101052171B1 (en) 2008-12-24 2009-12-18 Evaluation method of skin blackening tendency by ultraviolet rays
HK11113077.6A HK1158753B (en) 2008-12-24 2009-12-18 Method for evaluating tendency to skin pigmentation by ultraviolet light

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008327376A JP4473926B1 (en) 2008-12-24 2008-12-24 Evaluation method of skin darkening tendency by ultraviolet rays

Publications (2)

Publication Number Publication Date
JP4473926B1 true JP4473926B1 (en) 2010-06-02
JP2010151481A JP2010151481A (en) 2010-07-08

Family

ID=42287595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008327376A Expired - Fee Related JP4473926B1 (en) 2008-12-24 2008-12-24 Evaluation method of skin darkening tendency by ultraviolet rays

Country Status (4)

Country Link
JP (1) JP4473926B1 (en)
KR (1) KR101052171B1 (en)
CN (1) CN102239413B (en)
WO (1) WO2010073984A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5738720B2 (en) * 2011-03-24 2015-06-24 日本メナード化粧品株式会社 Melanin synthesis ability evaluation method and beauty advice method, and melanin synthesis ability evaluation system and beauty advice system using them
CN105588995B (en) * 2015-12-11 2018-08-14 深圳供电局有限公司 Line loss abnormity detection method for electric power metering automation system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2796646B1 (en) * 1999-07-23 2003-10-17 Oreal POLYPEPTIDE ISOLATED FROM THE STRATUM CORNEUM AND ITS USE
JP2003327376A (en) * 2002-05-10 2003-11-19 Toshiba Elevator Co Ltd Heater for elevator
EP1691199B1 (en) * 2003-10-01 2009-04-01 Shiseido Company Limited Method of predicting spot formation on the skin with the use of spot site-accelerating genes as indication and method of screening inhibitor for spot formation on the skin
JP2005272343A (en) * 2004-03-24 2005-10-06 Shiseido Co Ltd Method for inhibiting ultraviolet-induced apoptosis
KR101318521B1 (en) * 2005-08-23 2013-10-16 가오루 미야자키 Skin aging marker and technique for use thereof
CA2663749A1 (en) * 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
JP4675806B2 (en) * 2006-03-16 2011-04-27 日本メナード化粧品株式会社 Annexin activator

Also Published As

Publication number Publication date
CN102239413A (en) 2011-11-09
CN102239413B (en) 2014-03-26
KR20110070927A (en) 2011-06-24
JP2010151481A (en) 2010-07-08
WO2010073984A1 (en) 2010-07-01
KR101052171B1 (en) 2011-07-26
HK1158753A1 (en) 2012-07-20

Similar Documents

Publication Publication Date Title
JP4446009B1 (en) Wrinkle formation risk assessment method
JP4805794B2 (en) Method for detecting stratum corneum protein, method for evaluating epidermal turnover and method for evaluating skin condition using the same
JP5658696B2 (en) Evaluation method of skin stress accumulation
JP5065237B2 (en) Noninvasive evaluation method of local pathology of atopic dermatitis
JP4473926B1 (en) Evaluation method of skin darkening tendency by ultraviolet rays
JP2004340935A (en) Method for evaluating oxidized protein in horny layer
JP5775538B2 (en) Evaluation method of resistance to redness (redness) generation and reduction of whiteness induced by UV exposure
JP4446010B1 (en) Evaluation method of resistance to skin sunburn by ultraviolet rays.
JPWO2020195829A1 (en) How to evaluate the condition of the skin
JP4469762B2 (en) Sensitive skin evaluation method and evaluation kit
HK1199098A1 (en) Method of evaluating degree of skin stress accumulation
Mehta et al. A global perspective on safety and efficacy testing of hair care products
HK1158753B (en) Method for evaluating tendency to skin pigmentation by ultraviolet light
KR20210009981A (en) Method for evaluating resistance to skin sunburn by ultraviolet light
HK1158315A (en) Method for evaluating resistance to skin sunburn by ultraviolet light
JP2012039970A (en) How to test the degree of skin damage
HK1198451B (en) Method for evaluating resistance to ultraviolet damage
JP2017216941A (en) Diagnosis method of skin conditions
HK1186245A (en) Analysis method for skin stress accumulation
HK1187677A (en) Method of evaluating degree of skin stress accumulation

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100302

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100305

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130312

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4473926

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130312

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130312

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140312

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees